Iovance announced a workforce reduction of less than 20 percent following a slow commercial uptake of its tumor infiltrating lymphocyte (TIL) therapy, Amtagvi, approved for advanced melanoma. Despite being the first marketed cellular therapy of its kind, sales have not met initial forecasts, prompting a strategic restructuring to extend cash runway. The complex and costly manufacturing process and high list price contribute to the challenges faced in market penetration.